Calliditas Therapeutics AB

21.31 USD
-0.51 (-2.34%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Calliditas Therapeutics AB stock is up 9.28% since 30 days ago. The next earnings date is Aug 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 May’s closed higher than April.

About Calliditas Therapeutics AB

Calliditas Therapeutics AB (publ) focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy.